Genome Profiling is a digital health functional genomics company focused on decoding the sentinel power of the immune system’s global epigenetic response to acute and chronic health conditions, and to therapeutic interventions. We're leveraging those insights to create a pipeline of novel clinical diagnostic products that deliver transformational benefits to biopharmas, clinicians, patients and payers.
The Company employs proprietary chemical and machine learning methods/operations to discover blood-based, quantitative, epigenetic “fingerprints” called EpiMarkers. EpiMarkers phenotypically characterize early and disease-specific immune system activation and function by providing increased resolution of dynamic gene methylomics (activation or suppression of the immune systems functional genes) that can be translated into current clinical testing methods.
Genome Profiling EpiMarkers provide dynamic and detailed insights, that classical gene-mutation based methods cannot address, to enable novel precision diagnostic tests for acute and chronic diseases and to identify novel therapeutic targets.
The Company’s primary focus is to apply its critical intellectual property and a growing epigenetic profile database for the rapid discovery and controlled validation of immune system derived EpiMarkers in cancer and neurological disorders.
We're assembling a world-class team that is dedicated to bettering the lives of patients by improving the capabilities of our customers and partners.
Genome Profiling Leadership Team
Mr. Connor's professional experience is grounded in 12 years of successful sales and senior management experience with Hewlett-Packard's Analytical Systems Group (now Agilent Technologies) where he was responsible for their global lab automation systems business. Since Hewlett-Packard, Mr. Connor served as the Chairman and CEO of a several successful investor-backed software, life-science technology and information technology companies such as EMAX Solution Partners where he led its turn-around and capitalization from a challenged venture capital backed start-up into a successful enterprise software and e-commerce solution provider to the life-science research marketplace and its subsequent acquisition by a public company; ArtusLabs, where as Chairman Mr. Connor was instrumental to its development and acquisition by PerkinElmer; and Synthematix, where as founding outside Director Mr. Connor led its acquisition by a public company.
Prior to his tenure with GenPro, Mr. Connor was the Founding Chairman and Managing Director of The Longwood Group, an executive advisory consulting company to the Boards, CEOs and Executive teams of small-to-mid-size software, information technology and life science measurement and computation companies needing to better align their strategy and operational execution to accelerate growth, and to attract capital and acquirers to provide liquidity for investors. Over five years, he was instrumental in guiding five companies through a successful business transformation resulting in acquisitions by public companies. Concurrent with the Longwood Group, he served on an Advisory Board to the University of Delaware to promote entrepreneurism throughout the University’s faculty, aluminae, students and stakeholders; and served as Senior Advisor to Focus Investment Bank, a rapidly growing global M&A advisory firm to emerging growth and middle-market businesses.
Previously, in addition to his tenures at HP and EMAX, Mr. Connor was CEO of Panacya, a web and mobile application infrastructure management software company that was the precursor to BoxTone which was acquired by a public company; and he was Co-Founder and EVP Sales and Marketing for Automated Compliance Systems, a laboratory information management systems (LIMS) software company acquired by Beckman. Mr. Connor is a graduate of the College of Wooster, Wooster, Ohio with a BA in Biology and earned his MBA at Rutgers University.
Dr. Marsh is the visionary, inventor and leader of GenPro's core IP and computational capabilities. His expertise is at the nexus of molecular biology, epigenetics, statistics and advanced computational and machine learning technologies. As GenPro’s CSO, Adam leads the strategy and development of the EpiMarker Platform while also playing an active role developing and participating in customer and partner collaborations.
Dr. Marsh invented GenPro's foundational software technology while a faculty member in the Center for Bioinformatics and Computational Biology and the School of Marine Science and Policy at the University of Delaware. His primary research efforts focused on epigenetics of environmental imprinting in animals living in extreme environments (polar seas, deep oceans). His quantitative epigenetic profiling algorithm work started more than 10 years ago as an innovation of necessity to understand how invertebrate genomes thrived from generation to generation under the polar sea ice in Antarctica. Dr. Marsh is one of the earliest pioneers of computational epigenetics. The quantitative sensitivity and genome-wide breadth of his approach is the key attribute of the EpiMarker Platform’s ability to rapidly discover novel blood-based immune-system derived EpiMarkers for translation into transformational clinical tests and new epigenetic insights into the biology of the immune system.
Across all phases of his career computer programming, biostatistics and big-data have played a large role in defining his research vision and goals. Ever since handling stacks of punch cards for an IBM mainframe as an undergraduate researcher in 1980, the power of numerical processing through writing code and managing datasets has been central to his science.
Dr. Marsh received his Ph.D. from the University of Maryland, College Park, and pursued postdoctoral research in cell biology (Univ. New Hampshire, Durham), molecular biology and invertebrate immunology (Center of Marine Biotechnology, Univ. Maryland, Baltimore), and molecular physiology (Univ. Southern California, Los Angeles).
Dr. Anderson leads GenPro’s strategy and its execution with our biopharma collaboration partners. He is an oncology R&D leader with over 25 years of experience in the biotechnology and pharmaceutical industries. He earned his B.S .degree in Biochemistry from Iowa State University in Ames and received his Ph.D. in Biological Chemistry from the University of Michigan in Ann Arbor, followed by postdoctoral training at Merck Research Laboratories in West Point, Pennsylvania He is a cancer biologist and experienced drug developer with discovery and development of antibody-based therapeutics as his primary area of expertise.
Dr. Anderson has extensive large pharma experience, most recently with J&J (Janssen/Centocor), successfully initiating projects, developing agents utilizing novel and complex platforms, leading discovery and cross-functional compound development teams, and setting overall discovery and development strategy. He led teams that have taken multiple antibody based anti-cancer therapeutics to the NME stage, with several progressing to IND and clinical evaluation. He has also served as an adviser to life science focused venture capital firms, drug development accelerators and start-ups, and public biotechnology companies. In addition to his focus on cancer biology Dr. Anderson has expertise in the fields of biomarker discovery and development, T-cell redirection, immuno-oncology, and innate immune function.
Scott L. Frankenfield
Scott Frankenfield is GenPro’s Chief Financial Officer responsible for the financial strategy and operations of the company. Mr. Frankenfield has over 25 years of experience in both public and private accounting in a wide range of leadership, management and advisory positions.
In the role of Chief Financial Officer, Mr. Frankenfield is committed to maximizing shareholder value and maintaining a high level of integrity in the Company’s financial operations. He provides executives with timely financial statements, ongoing cash flow projections, oversight over accounting and finance operations, as well as design and maintenance of the financial reporting structures.
Prior to joining GenPro, Mr. Frankenfield operated a CPA practice and was also the Director of Accounting and Audit at a suburban Philadelphia CPA firm. He served as the Chief Financial Officer and held various financial management positions with several large manufacturing corporations.
Mr. Frankenfield received an MBA from Moravian College and a Masters in Tax from Villanova University and is a certified public accountant.
Mr. Goldman leads the development, scalability, security and operations of the cloud based infrastructure provisioning the EpiMarker Platform and the performance of the integrated collection of applications and technologies running on it that deliver results and information to our customers. Mr. Goldman has significant experience architecting and developing complex clould-based systems that manage large volumes of complex data across a wide range of vertical industries and technology stacks, including the big-data genomics solutions.
Mr. Goldman started his career in database management system research and product development, and then moved into a solution integration role -- founding and growing two solution integration firms -- Information Technologists and ICON Solutions. Both companies focused on delivering advanced information technology to solve business problems for enterprise customers. After selling his interest in ICON Solutions, Mr. Goldman founded Fortera, a company that managed risk in IT projects by insuring successful completion.
Most recently, before joining GenPro, Mr. Goldman provided IT strategy, architectural, and project management services through 408 West, LLC. His most recent project was directing product development for a data mining company targeting fraud detection in international trade.
Mr. Goldman is a graduate of the Wharton School of Business and Finance of the University of Pennsylvania.
Scientific Advisory Board
James Serum, Ph.D.
Dr. Serum received a B. A. in Chemistry from Hope College in 1965 and was awarded a Ph.D. degree in Organic Chemistry in 1969 from the University of Colorado. His doctorate research was directed toward studies in Mass Spectrometry. Following his graduate studies, he taught and did research at the University of Ghent, Belgium. He spent a year at Rice University as a Welch Fellow, and then joined the staff at Cornell University as Director of the National Institutes of Health High Resolution Mass Spectrometry Facility.
Dr. Serum joined the Hewlett-Packard Company in 1973 as Applications Chemist for Mass Spectrometry. Since then he has held a number of management positions, including Technical Support Manager for Mass Spectrometry in Europe (Paris, France); Marketing Manager for Mass Spectrometry and Spectroscopy at the Scientific Instruments Division; R&D Manager at the same division; and R&D Manager for the Avondale Division (Laboratory Automation and Chromatography Instrumentation). Since 1984 he has held Business Unit level positions as Operations Manager for Laboratory Automation Systems, Automated Chemical Systems Operation and Analytical Group Research & Development Manager. In 1992 Dr. Serum was named General Manager for Mass Spectrometry, Infrared, and Protein Chemical Systems. He was the founder of HP’s Bioscience Products business. He has served as chairman of HP's Bioscience Council, co-chairman of the Hewlett-Packard R&D Council and the Pharmaceutical Business Council. He retired from Hewlett Packard in August 1999 to co-found Viaken Systems Inc, where he was a Director and served as Executive Vice President and Chief Operating Officer. Dr. Serum has been a Venture Partner with Flagship Ventures and until retiring in 2011, served as President of Scitek Ventures, a science and technology consulting firm that he founded in 2002. In 2002 he was elected as a lifetime National Associate of the National Academy of Sciences and in 2004 he was elected to serve on the Visiting Committee for Advanced Technology of NIST. In 2005, Dr. Serum was named to the President’s Advisory Board for Advanced Technology at the Research Corporation. He has served as a member of the Board of Directors for a number of emerging technology based companies. In 2008, he was elected as Chairman of the Visiting Committee for Advanced Technology for NIST. Dr. Serum retired from his company, Scitek Ventures in 2011. He remains actively involved in the future of science and technology in the US and has testified several times in Congress related to this topic. In 2013, Dr. Serum organized and chaired a National Workshop at NIST on advanced technology related to an improved measurement “diagnostic” for Lyme disease. Although officially retired, Dr. Serum remains active in research collaborations with Johns Hopkins Medical School and NIST involving improved detection methodologies for Lyme disease. He is also a science and business advisor to a young company, GenPro, involving technology for detection of a variety of very early stage cancers and other diseases. Dr. Serum serves on the Board of Directors of the non-profit organization, tranSMART Foundation, which is a member-driven non-profit foundation developing an open-source / open-data community around the tranSMART and OpenBEL translational research platforms.
Andre Ruzycky, Ph.D. , MBA
Dr. Ruzycky is a senior corporate development executive who has served in senior innovation leadership roles for several top global medical device and diagnostics companies. Most recently Dr. Ruzycky was Vice President, Strategy and Business Development for Becton Dickinson's Diagnostic Systems Group. Previously, he was VP Corporate Development for Hologic Inc., and Vice President, Technology Assessment at Johnson & Johnson’s Ortho Clinical Diagnostics Division.
Dr. Ruzycky earned a BS Degree (biochemistry) from McMaster University, a PhD in Pharmacology from the University of Buffalo, and a MBA form the University of Pittsburgh. He began his career in medical research with Research Fellowships at Harvard Medical School and at the University of California San Francisco, followed by a faculty appointment at the University of Pittsburgh School of Medicine. He brings extensive experience in novel IVD product development and investment with focus on cancer and infectious disease diagnostics and diagnostics platforms.
Robert T. McCormack, Ph.D.
Dr. McCormack is Principal of RMCC, LLC, where he advises companies in liquid biopsy development and testing. Bob is also a member of the FNIH Cancer Steering Committee and co-leads its efforts to develop well-validated reference materials for ctDNA testing.
Dr. McCormack has thirty years of invitro diagnostics experience in clinical, regulatory, medical and scientific affairs. He served in R&D leadership positions at academic institutions, small biotechs, large diagnostic companies, and in the pharmaceutical sector. While at J&J he was a founding member and General Manager of Veridex, LLC, Cellular Technologies, which helped define the liquid biopsy space. Prior to Veridex he was Head of Biomarker Strategy for the Disease Interception Group in Janssen Pharmaceutical R&D, and Vice President of Clinical Affairs for Ortho-Clinical Diagnostics.
Dr. McCormack received his BS degree from the University of Wisconsin, River Falls, and his MS and PhD degrees from the University of Minnesota.
Ian Wright, CBIOL, MRSB
Ian was formerly with Siemens Healthcare Diagnostics where he was VP, head of the Strategic Innovation group where he had global responsibility for Siemens innovation growth strategy earning industry-wide regard for his expertise. Prior to taking the Chief Strategy Officer for the Precision Medicine Initiative at Cedars Sinai, Ian was Chief Science Officer of Cedar Sinai’s Advanced Clinical Bio-Systems Institute. His career spans over 30 years in life-science commercialization and technology development. Ian has been a valued advisor to GenPro since its founding in 2014.